OpenAI absorbs biotech AI startup Orchestra Bio to bolster Rosalind
OpenAI has acquired Orchestra Bio, a startup that builds AI agents for operational work in drug discovery. The deal terms were not disclosed; Orchestra had raised roughly $20 million by 2025. Its team and technology will be folded into OpenAI's Rosalind life-sciences model and Workbench tool.
OpenAI said on its website that it bought Orchestra Bio, a four-year-old software company focused on AI biotech. The purchase price was not revealed. By 2025, Orchestra had reportedly raised about $20 million from investors including Andreessen Horowitz, Atria, and 8VC.
Orchestra’s agents assist biotech firms with operational chores in drug development, such as financial tracking and clinical-trial scheduling. OpenAI plans to merge its people and tools into Rosalind, its life-sciences model, and Rosalind Workbench, which supports experiment planning and results analysis. Moderna and Novo Nordisk are named customers.
The deal may affect biotech researchers and pharma firms by putting more operational AI into OpenAI’s life-sciences tools, potentially changing how experiments and trial logistics are managed. Smaller AI vendors could face pressure if large labs keep expanding into industry-specific software. Patients might eventually see effects through faster or more coordinated drug-development work, though the acquisition’s actual impact remains uncertain.